Clarivate Plc Earnings Recaps
Q2 2026
Aug 2, 2026
Clarivate's shares plunged 16.2% following the quarter, reflecting investor disappointment mainly due to cautious outlook and ongoing deceleration in the Intellectual Property segment’s growth despite progress in AI initiatives and stable organic ACV growth in other segments.
Key takeaways
- Organic ACV growth improved modestly to 1.5% overall, driven by 2% growth in Academia & Government and Life Sciences & Healthcare segments.
- Intellectual Property segment’s recurring organic revenue remained flat, with growth only expected in the second half, signaling ongoing challenges.
- Profit margin expanded slightly to over 42%, aided by disciplined cost management.
- Management announced the divestiture of the Life Sciences & Healthcare segment, aiming to sharpen focus on AI-driven intelligence and simplify the business model.
- New AI product launches, including Nexus Connect and IP-1, indicate innovation progress but have yet to reverse investor concerns about near-term growth trajectory.
Q2 2025
Aug 1, 2025
Clarivate delivered solid Q2 2025 results, with organic revenue growth driven by improved renewal rates and new business wins, while reinforcing its Value Creation Plan focused on AI innovation.
Key takeaways
- Organic ACV grew 1.3% year-over-year, with significant contributions from subscription renewals and new acquisitions.
- Adjusted EBITDA margin improved by 50 basis points to 41%, reflecting successful cost efficiencies across the organization.
- Free cash flow remained robust, generating $50 million in Q2 and totaling $161 million for the first half of the year.
- A&G segment subscription revenue increased to 93% of total revenue, with a commendable 96% renewal rate achieved.
- Clarivate reaffirms its full-year 2025 outlook, underpinned by momentum in AI-led product development and strategic business optimization.